Western equine encephalitis

Summary

Western equine encephalitis (MONDO:0019380) is a disease and 2 clinical trials. A subtype of Alphavirus infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (United States) [Orphanet-validated]
• Clinical trials: 2

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.02	United States	Validated
Point prevalence	1-9 / 1 000 000		Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	western equine encephalitis
Mondo ID	MONDO:0019380
EFO	EFO:0007546
MeSH	D020241
Orphanet	83593
DOID	DOID:10843
ICD-10-CM	A83.1
ICD-11	1543765035
NCIT	C85227
SNOMED CT	47523006
UMLS	C0153064
MedGen	57778
GARD	0007888
MedDRA	10014614
Is cancer (heuristic)	no

Also known as: Western equine encephalitis virus caused infectious encephalitis · Western equine encephalitis virus infectious encephalitis · Western equine encephalomyelitis

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Togaviridae infectious disease › Alphavirus infectious disease › western equine encephalitis

Related subtypes (5): O’nyong’nyong fever, Barmah forest virus disease, Ross river fever, Venezuelan equine encephalitis, chikungunya

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02466750	PHASE2	UNKNOWN	Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine
NCT03879603	PHASE1	COMPLETED	VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults